A Transcriptional Program Modulating Epithelial Death and Innate Function - Project 1
调节上皮死亡和先天功能的转录程序 - 项目 1
基本信息
- 批准号:10204080
- 负责人:
- 金额:$ 43.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-01-03 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcetyltransferaseAcuteAcute Lung InjuryAdult Respiratory Distress SyndromeAmino AcidsAttenuatedBehaviorBindingBiologicalCell DeathCell NucleusCell SurvivalCellsCellular biologyCessation of lifeChemicalsClinicalCoupledCritical IllnessDataDiseaseDistalEffector CellEndotoxinsEpigenetic ProcessEpithelialEpithelial CellsEquilibriumExhibitsExperimental ModelsFoundationsFunctional disorderGene SilencingGenesGenetic ModelsGenetic TranscriptionHistone AcetylationHost DefenseHumanImmuneImmune responseImmunological ModelsImmunosuppressionImpairmentIn VitroInfectionInflammationInflammatoryInnate Immune ResponseLifeLinkLongevityLungLung InflammationLymphocyteLysineMediatingModelingMolecularNatural ImmunityNuclearPathway interactionsPatientsPharmacologyPharmacotherapyPhasePlayPneumoniaPre-Clinical ModelPrognosisPropertyProtein BiosynthesisProtein DephosphorylationProteinsProteolysisRegulationRoleSepsisSyndromeSystemTestingTranscription CoactivatorUbiquitinUbiquitin-mediated Proteolysis Pathwayalveolar epitheliumdesignepigenetic markerfightinggene repressionhistone modificationimmune functionin vivoinhibitor/antagonistlung injurymodel designmolecular modelingmortalitynovelopportunistic pathogenprogramsrespiratorysmall moleculesuperinfectionubiquitin-protein ligase
项目摘要
Acute Respiratory Depress Syndrome (ARDS) can be a devastating disorder and prior
studies have focused mainly on its hyper-inflammatory state. However, mounting data
suggest that immune suppression partakes in this disorder, the molecular mechanisms of
which remain unclear. This Project investigates a unique molecular model whereby a lysine
acetyltransferase termed general control of amino acid synthesis protein 5-like 2 (Gcn5l2),
normally targeted for its disposal in cells by a ubiquitin E3 ligase subunit, Fbxo24, executes
alveolar epithelial cell death and suppression of genes involved in innate immunity through
histone modification. Our hypothesis is that Gcn5l2, normally kept in check by ubiquitin-
mediated degradation, is an endotoxin-responsive executioner of innate immune suppression
and epithelial cellular death in experimental ARDS. As a corollary to this hypothesis, we
propose that Gcn5l2 chemical inhibition will attenuate acetyltransferase activity. Hence, in
this application we will first elucidate how endotoxin increases Gcn5l2 levels by abrogating its
Fbxo24 E3 ubiquitin ligase mediated proteolysis in experimental lung injury (Aim 1). We will
specifically investigate how Fbxo24 targets Gcn5l2 for its degradation using complementary
in vitro and in vivo genetic models and then evaluate how endotoxin abrogates molecular
interaction of these partners. Next, we will optimize the pharmacologic design and test a
novel small molecule that exhibits distinct, and yet complementary immune modulatory and
cytoprotective properties in 2-hit models of immune suppression and in an ex vivo isolated
human lung system (Aim 2). These studies will provide a new pathobiologic model of immune
dysregulation that will serve as a platform for generating small molecule modulators that
optimize epithelial cell survival and restore host defense in subjects with severe critical
illness.
急性呼吸抑制综合征(ARDS)可能是一种毁灭性的疾病,
研究主要集中在其高度炎症状态。然而,安装数据
表明免疫抑制参与了这种疾病,
目前还不清楚该项目研究了一种独特的分子模型,
乙酰转移酶称为氨基酸合成的一般控制蛋白5-样2(Gcn 512),
通常被泛素E3连接酶亚基Fbxo 24在细胞中处理,
肺泡上皮细胞死亡和先天免疫相关基因的抑制,
组蛋白修饰我们的假设是Gcn 5l 2,通常由泛素控制-
介导的降解,是先天性免疫抑制的内毒素应答执行者
和上皮细胞死亡。作为这一假设的推论,我们
提出Gcn 5l 2化学抑制将减弱乙酰转移酶活性。所以在
在本申请中,我们将首先阐明内毒素是如何通过消除Gcn 5l 2的活性来增加Gcn 5l 2水平的。
Fbxo 24 E3泛素连接酶介导的实验性肺损伤中的蛋白水解(目的1)。我们将
具体地研究Fbxo 24如何靶向Gcn 5l 2用于其降解,
体外和体内遗传模型,然后评估内毒素如何消除分子
这些合作伙伴的互动。下一步,我们将优化药理学设计,并测试一个
一种新的小分子,其表现出独特的但互补的免疫调节作用,
在免疫抑制的2次打击模型中和在离体分离的
人肺系统(目标2)。这些研究将提供一种新的免疫病理生物学模型
调节异常,其将作为产生小分子调节剂的平台,
优化上皮细胞存活并恢复严重危重患者的宿主防御
病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rama K Mallampalli其他文献
Regulation of inflammasomes by ubiquitination
泛素化对炎症小体的调节
- DOI:
10.1038/cmi.2016.15 - 发表时间:
2016-04-11 - 期刊:
- 影响因子:19.800
- 作者:
Joseph S Bednash;Rama K Mallampalli - 通讯作者:
Rama K Mallampalli
Vascular Endothelial Growth Factor (VEGF) Induces Airway Epithelial Cell Proliferation and Surfactant Protein Gene Expression in Human Fetal Lung In Vitro † 242
血管内皮生长因子(VEGF)在体外诱导人胎儿肺气道上皮细胞增殖和表面活性蛋白基因表达†242
- DOI:
10.1203/00006450-199804001-00263 - 发表时间:
1998-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Michael J Acarregui;Kristie Ramirez;Karen R Brown;Rama K Mallampalli - 通讯作者:
Rama K Mallampalli
Identification of Sex-Specific Differences in Surfactant Synthesis within the CDP-Choline Pathway
- DOI:
10.1203/00006450-199904020-00340 - 发表时间:
1999-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Diann M McCoy;Ronald G Salome;David J Kusner;Shankar S Iyar;Rama K Mallampalli - 通讯作者:
Rama K Mallampalli
Rama K Mallampalli的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rama K Mallampalli', 18)}}的其他基金
Developing a Novel E3 Ligase based Anti-inflammatory for ARDS
开发基于 E3 连接酶的新型抗 ARDS 抗炎药物
- 批准号:
10557164 - 财政年份:2022
- 资助金额:
$ 43.19万 - 项目类别:
Developing a Novel E3 Ligase based Anti-inflammatory for ARDS
开发基于 E3 连接酶的新型抗 ARDS 抗炎药物
- 批准号:
10366763 - 财政年份:2022
- 资助金额:
$ 43.19万 - 项目类别:
Cardiolipin as a Novel Mediator of Acute Lung Injury
心磷脂作为急性肺损伤的新型调节剂
- 批准号:
8608045 - 财政年份:2014
- 资助金额:
$ 43.19万 - 项目类别:
Regulation of Cardiolin Byosynthesis in Epithelial Injury
上皮损伤中心磷脂合成的调节
- 批准号:
8643329 - 财政年份:2014
- 资助金额:
$ 43.19万 - 项目类别:
A New Genus of Ubiquitin-Based Anti-inflammatories for COPD
一类新的基于泛素的慢性阻塞性肺病抗炎药
- 批准号:
8751858 - 财政年份:2014
- 资助金额:
$ 43.19万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
Identification of novel phenotypes of acute lung injury using multimodal longitudinal data
使用多模态纵向数据识别急性肺损伤的新表型
- 批准号:
MR/Y000404/1 - 财政年份:2023
- 资助金额:
$ 43.19万 - 项目类别:
Fellowship














{{item.name}}会员




